Carma L Bylund1,2,3, Elisa S Weiss4, Margo Michaels5, Shilpa Patel6, Thomas A D'Agostino1, Emily B Peterson7, Maria Christina Binz-Scharf8, Natasha Blakeney9, M Diane McKee10. 1. 1 Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. 2 Weill Cornell Medicine-Qatar, Doha, Qatar. 3. 3 Hamad Medical Corporation, Doha, Qatar. 4. 4 The Leukemia & Lymphoma Society, Rye Brook, NY, USA. 5. 5 Health Care Access and Action Consulting, Boston, MA, USA. 6. 6 Department of Population Health, NYU Medical Center, New York, NY, USA. 7. 7 Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA. 8. 8 Colin Powell School for Civic and Global Leadership, The City College of New York, New York, NY, USA. 9. 9 Education Network to Advance Cancer Clinical Trials, Bethesda, MD, USA. 10. 10 Department of Family and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract
BACKGROUND/AIMS: Cancer clinical trials give patients access to state-of-the-art treatments and facilitate the translation of findings into mainstream clinical care. However, patients from racial and ethnic minority groups remain underrepresented in clinical trials. Primary care physicians are a trusted source of information for patients, yet their role in decision-making about cancer treatment and referrals to trial participation has received little attention. The aim of this study was to determine physicians' knowledge, attitudes, and beliefs about cancer clinical trials, their experience with trials, and their interest in appropriate training about trials. METHODS: A total of 613 physicians in the New York City area primarily serving patients from ethnic and racial minority groups were invited via email to participate in a 20-min online survey. Physicians were asked about their patient population, trial knowledge and attitudes, interest in training, and personal demographics. Using calculated scale variables, we used descriptive statistical analyses to better understand physicians' knowledge, attitudes, and beliefs about trials. RESULTS: A total of 127 physicians completed the survey. Overall, they had low knowledge about and little experience with trials. However, they generally had positive attitudes toward trials, with 41.4% indicating a strong interest in learning more about their role in trials, and 35.7% indicating that they might be interested. Results suggest that Black and Latino physicians and those with more positive attitudes and beliefs were more likely to be interested in future training opportunities. CONCLUSION: Primary care physicians may be an important group to target in trying to improve cancer clinical trial participation among minority patients. Future work should explore methods of educational intervention for such interested providers.
BACKGROUND/AIMS: Cancer clinical trials give patients access to state-of-the-art treatments and facilitate the translation of findings into mainstream clinical care. However, patients from racial and ethnic minority groups remain underrepresented in clinical trials. Primary care physicians are a trusted source of information for patients, yet their role in decision-making about cancer treatment and referrals to trial participation has received little attention. The aim of this study was to determine physicians' knowledge, attitudes, and beliefs about cancer clinical trials, their experience with trials, and their interest in appropriate training about trials. METHODS: A total of 613 physicians in the New York City area primarily serving patients from ethnic and racial minority groups were invited via email to participate in a 20-min online survey. Physicians were asked about their patient population, trial knowledge and attitudes, interest in training, and personal demographics. Using calculated scale variables, we used descriptive statistical analyses to better understand physicians' knowledge, attitudes, and beliefs about trials. RESULTS: A total of 127 physicians completed the survey. Overall, they had low knowledge about and little experience with trials. However, they generally had positive attitudes toward trials, with 41.4% indicating a strong interest in learning more about their role in trials, and 35.7% indicating that they might be interested. Results suggest that Black and Latino physicians and those with more positive attitudes and beliefs were more likely to be interested in future training opportunities. CONCLUSION: Primary care physicians may be an important group to target in trying to improve cancer clinical trial participation among minority patients. Future work should explore methods of educational intervention for such interested providers.
Entities:
Keywords:
Cancer clinical trials; clinical trials knowledge; minority patients; primary care physicians
Authors: Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Ari Umutyan; Christine Chiechi; Laurel A Beckett; Debora A Paterniti; Corinne Turrell; David R Gandara; Sharon W Davis; Ted Wun; Moon S Chen; Primo N Lara Journal: Cancer Date: 2008-01-01 Impact factor: 6.860
Authors: John H Stewart; Alain G Bertoni; Jennifer L Staten; Edward A Levine; Cary P Gross Journal: Ann Surg Oncol Date: 2007-08-08 Impact factor: 5.344
Authors: Lauren M Hamel; David W Dougherty; Terrance L Albrecht; Mark Wojda; Alice Jordan; Tanina F Moore; Nicole Senft; Michael Carducci; Elisabeth I Heath; Mark A Manning; Louis A Penner; Seongho Kim; Susan Eggly Journal: JCO Oncol Pract Date: 2019-12-02
Authors: Carma L Bylund; Margo Michaels; Elisa S Weiss; Shilpa Patel; Thomas A D'Agostino; Maria Christina Binz-Scharf; Diane McKee Journal: J Cancer Educ Date: 2021-10 Impact factor: 1.771